HSBC: Maintaining the Zoetis (ZTS.US) rating, adjusted from buy to buy rating, and adjusted the target price from $230.00 to $225.00.
Zoetis Analyst Ratings
HSBC Maintains Buy on Zoetis, Lowers Price Target to $225
HSBC Adjusts Price Target on Zoetis to $225 From $230
Goldman Sachs: Maintains Zoetis (ZTS.US) rating, adjusted from buy to buy rating, and adjusted target price from $223.00 to $196.00.
Zoetis Analyst Ratings
Piper Sandler Issues a Buy Rating on Zoetis (ZTS)
Goldman Sachs Adjusts Price Target on Zoetis to $196 From $223
Redburn Atlantic Adjusts Price Target on Zoetis to $220 From $230, Keeps Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
Stifel: Maintaining the Zoetis (ZTS.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $195.00 to $180.00.
Zoetis Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zoetis (ZTS)
Stifel Adjusts Price Target on Zoetis to $180 From $195
Barclays: Maintaining the Zoetis (ZTS.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $260.00 to $230.00.
Zoetis Analyst Ratings
Barclays Maintains Overweight on Zoetis, Lowers Price Target to $230
Zoetis (ZTS) Gets a Buy From Bank of America Securities
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
Piper Sandler: Reiterates the Zoetis (ZTS.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $220.00 to $195.00.